Holen Sie sich die Stockscreener-App
43.49
2.79%
-1.25
Vorhandelsmarkt:
43.46
-0.03
-0.07%
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Vaxcyte stock maintains Buy rating at Jefferies as Phase 3 trial begins - Investing.com Canada
Vaxcyte Doses First Patients in Phase 3 Trial of VAX-31 in Invasive Pneumococcal Disease, Pneumonia - marketscreener.com
Vaxcyte announces first participants dosed in OPUS Phase 3 trial of VAX-31 - TipRanks
Vaxcyte begins phase 3 trial of pneumococcal vaccine VAX-31 - Investing.com
Vaxcyte (PCVX) Begins Phase 3 Study for Pneumonia Vaccine - GuruFocus
Vaxcyte says topline results from OPUS trial expected in Q4 2026 - marketscreener.com
Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026 - TradingView
Vaxcyte begins phase 3 trial of pneumococcal vaccine VAX-31 By Investing.com - Investing.com South Africa
Vaxcyte Finalizes Trial Design for VAX-31, Aiming to Set New Standard for Adult Pneumococcal Vaccines in Consultation with FDA - Quiver Quantitative
Vaxcyte Doses First Participants in the OPUS Phase 3, - GlobeNewswire
Vaxcyte Inc. (PCVX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vaxcyte (BIT:1PCVX) Price Target Increased by 17.53% to 85.05 - Nasdaq
Vaxcyte (NASDAQ:PCVX) Trading Down 3.7%Here's Why - MarketBeat
Vaxcyte, Inc. $PCVX Shares Purchased by Saturn V Capital Management LP - MarketBeat
American Century Companies Inc. Sells 236,002 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
JPMorgan Chase & Co. Decreases Stake in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte (NASDAQ:PCVX) Shares Gap DownHere's What Happened - MarketBeat
Can Vaxcyte Inc. (5VA) stock attract analyst upgrades2025 Technical Patterns & Growth Focused Stock Pick Reports - Newser
Quadrature Capital Ltd Takes $1.36 Million Position in Vaxcyte, Inc. $PCVX - MarketBeat
Is Vaxcyte Inc. (5VA) stock a top hedge fund pickJuly 2025 Short Interest & Low Risk High Reward Ideas - Newser
Transcript : Vaxcyte, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 02 - marketscreener.com
Transcript : Vaxcyte, Inc. Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference, Nov-11-2025 02 - marketscreener.com
Moderna Falls as FDA Vows to Impose New Vaccine Requirements - Bloomberg.com
S&P 500 Futures Fall in Premarket Trading; Vaxcyte, Cipher Mining Lag - Barron's
XTX Topco Ltd Has $1.36 Million Position in Vaxcyte, Inc. $PCVX - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Lowers Position in Vaxcyte, Inc. $PCVX - MarketBeat
Franklin Resources Inc. Lowers Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
DNB Asset Management AS Acquires 6,924 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Entropy Technologies LP Makes New Investment in Vaxcyte, Inc. $PCVX - MarketBeat
Why Vaxcyte Inc. (5VA) stock remains stableJuly 2025 Closing Moves & Short-Term High Return Ideas - BỘ NỘI VỤ
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Cash per share of Vaxcyte, Inc. – BX:PCVX - TradingView
8,754 Shares in Vaxcyte, Inc. $PCVX Purchased by AXQ Capital LP - MarketBeat
Intech Investment Management LLC Sells 19,443 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
EBIT per share of Vaxcyte, Inc. – DUS:5VA - TradingView
Mizuho Securities Sticks to Their Buy Rating for Vaxcyte (PCVX) - The Globe and Mail
Vaxcyte (PCVX): Evaluating Valuation After a 48% Three-Month Share Price Rebound - Yahoo Finance
How Vaxcyte Inc. stock reacts to Fed rate cutsWeekly Trade Report & Free Technical Pattern Based Buy Signals - newser.com
Is Vaxcyte Inc. stock vulnerable to regulatory risksEarnings Growth Report & Risk Managed Investment Entry Signals - newser.com
Will Vaxcyte Inc. stock continue upward momentumQuarterly Trade Review & Accurate Trade Setup Notifications - newser.com
Vaxcyte stock price target raised to $77 from $60 at Leerink Partners By Investing.com - Investing.com South Africa
Vaxcyte stock price target raised to $77 from $60 at Leerink Partners - Investing.com Australia
PCVX: 31-Valent vaccine nears phase III, targeting major market growth and expanded global demand - TradingView
Vaxcyte (PCVX) Price Target Decreased by 17.52% to 83.49 - MSN
What analyst consensus says on Vaxcyte Inc. stockTrade Entry Report & High Conviction Trade Alerts - newser.com
(PCVX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Can momentum traders help lift Vaxcyte Inc.July 2025 Action & Precise Swing Trade Entry Alerts - newser.com
Is Vaxcyte Inc. stock poised for growthEarnings Trend Report & Daily Technical Forecast Reports - newser.com
Will Vaxcyte Inc. benefit from macro trendsPortfolio Risk Summary & Safe Capital Allocation Plans - newser.com
Vaxcyte, Inc.Common Stock (NQ: PCVX - Markets Financial Content
Vaxcyte Inc Stock Analysis and ForecastStock Split Announcements & High Profit Portfolio Growth - earlytimes.in
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):